MiMedx Group, Inc. — News

MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, July 29, 2026.

globenewswire.com - 2026-07-20 08:00:00

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext.

prnewswire.com - 2026-05-21 15:45:00

MARIETTA, Ga., May 21, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the Craig-Hallum 23 rd Annual Institutional Investor Conference on Thursday, May 28, 2026 in Minneapolis, MN. Investors interested in meeting with senior management may contact their Craig-Hallum representative.

globenewswire.com - 2026-05-21 08:45:00

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG). Such investors are advised to contact Danielle Peyton at  [email protected]  or 646-581-9980, ext. 7980.

globenewswire.com - 2026-05-19 18:15:00

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group, Inc. - MDXG PR Newswire

gurufocus.com - 2026-05-15 00:00:00

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-05-14 23:01:00

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG).  Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

globenewswire.com - 2026-05-12 16:52:00

Investors need to pay close attention to MDXG stock based on the movements in the options market lately.

zacks.com - 2026-05-11 15:40:29

MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited.

seekingalpha.com - 2026-05-09 05:04:28

Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company's Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga. , May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide.

globenewswire.com - 2026-05-08 08:00:00

Flowable Biomimetic Matrix Adds Self-Assembling Peptide Technology to Company's Portfolio G4Derm Plus Added to Premier and Vizient GPO Agreements MARIETTA, Ga., May 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of G4Derm Plus, with initial sales of the product already delivered to customers nationwide.

globenewswire.com - 2026-05-08 08:00:00

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MiMedx Group, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG).  Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext.

prnewswire.com - 2026-05-07 10:00:00

MiMedx Group, Inc. (MDXG) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-04-29 23:41:33

MiMedx (MDXG) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.06 per share a year ago.

zacks.com - 2026-04-29 19:41:33

Reports  First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations Management to Host Conference Call Today, April 29, 2026, at 4:30 PM ET MARIETTA, Ga., April 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the first quarter 2026.

globenewswire.com - 2026-04-29 16:01:00